A Danish pharmaceutical company is intensifying efforts to combat obesity in the Philippines, warning that the growing health crisis could hinder economic productivity and the nation's ability to maintain a healthy workforce.
Novo Nordisk Philippines launched its 'Live Lighter' campaign as obesity rates continue to climb, impacting not only individual health but also families and communities. The company has partnered with Cebu-based pharmacy chain Rose Pharmacy to expand access to obesity and diabetes screening services in the Visayas and Mindanao regions.
Wei Sun, general manager of Novo Nordisk Philippines, emphasized the importance of partnerships in addressing obesity, which he described as a chronic disease affecting millions of Filipinos. 'Obesity is a chronic, serious disease affecting over 30 million Filipinos, and we know we are not going to be able to address it alone. We have to work with partners,' Sun said.
The collaboration aims to bring science-based healthcare solutions and advocacy efforts closer to communities in these regions. 'We are very happy that we can bring some of our expertise, innovations and advocacy efforts to this part of the Philippines,' Sun added.
Rose Pharmacy noted that many Filipinos still rely on self-medication and delay seeking professional medical care due to limited awareness and access to treatment options. The partnership seeks to improve awareness, early detection, and access to healthcare services outside major urban centers through Rose Pharmacy's network of more than 465 stores across the Visayas and Mindanao.
The company stressed that people in the provinces deserve more accessible healthcare options and the same level of care. Under the partnership, select Rose Pharmacy branches will offer screening services for individuals with obesity and diabetes.
Economic Impact
Health experts warn that rising obesity rates are becoming an economic concern, as weight-related diseases increase healthcare costs, reduce worker productivity, and contribute to absenteeism. Recent estimates from the EpiCOb-PH study indicate that obesity cost the Philippine economy approximately P1.9 trillion in 2025, equivalent to 7.3 percent of gross domestic product. This reflects the growing burden of noncommunicable diseases on public health spending and labor productivity.
Executives said improving obesity management is critical to maintaining a productive workforce amid concerns about the long-term impact of chronic diseases on economic growth.
